275,000 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Purchased by Parkwood LLC

Parkwood LLC bought a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 275,000 shares of the company’s stock, valued at approximately $3,484,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in DAWN. R Squared Ltd purchased a new stake in shares of Day One Biopharmaceuticals in the fourth quarter valued at approximately $31,000. Tower Research Capital LLC TRC boosted its position in shares of Day One Biopharmaceuticals by 911.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company’s stock worth $135,000 after purchasing an additional 9,603 shares in the last quarter. E Fund Management Co. Ltd. acquired a new position in shares of Day One Biopharmaceuticals during the 4th quarter worth $143,000. KLP Kapitalforvaltning AS acquired a new position in shares of Day One Biopharmaceuticals during the 4th quarter worth $150,000. Finally, Man Group plc purchased a new position in shares of Day One Biopharmaceuticals in the 4th quarter valued at about $162,000. Institutional investors and hedge funds own 87.95% of the company’s stock.

Insider Transactions at Day One Biopharmaceuticals

In related news, CEO Jeremy Bender sold 12,048 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $144,094.08. Following the completion of the transaction, the chief executive officer now directly owns 128,015 shares in the company, valued at approximately $1,531,059.40. This represents a 8.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel Adam Dubow sold 4,646 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $55,566.16. Following the completion of the sale, the general counsel now directly owns 39,602 shares in the company, valued at approximately $473,639.92. The trade was a 10.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 21,064 shares of company stock worth $251,925 over the last quarter. 6.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts recently commented on DAWN shares. HC Wainwright reissued a “buy” rating and set a $36.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. Wedbush reaffirmed an “outperform” rating and set a $25.00 price objective on shares of Day One Biopharmaceuticals in a report on Wednesday, May 7th. Needham & Company LLC dropped their target price on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. The Goldman Sachs Group reduced their price target on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating on the stock in a report on Tuesday, March 25th. Finally, JPMorgan Chase & Co. cut their price objective on Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating for the company in a research report on Wednesday, March 5th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Day One Biopharmaceuticals has a consensus rating of “Buy” and a consensus price target of $30.57.

Day One Biopharmaceuticals Trading Down 3.8%

NASDAQ:DAWN opened at $6.33 on Wednesday. Day One Biopharmaceuticals, Inc. has a 12-month low of $6.10 and a 12-month high of $17.14. The firm has a market cap of $641.62 million, a price-to-earnings ratio of -6.15 and a beta of -1.24. The company’s 50-day moving average is $7.58 and its two-hundred day moving average is $10.97.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Tuesday, May 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.11. The firm had revenue of $30.76 million for the quarter, compared to analyst estimates of $30.28 million. On average, equities research analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.